Revvity, Inc. (RVTY) Q3 2025 Financial Results Summary
Release Date: October 27, 2025
Revvity, Inc. has announced its financial results for the third quarter ended September 28, 2025. Below is a concise summary of the key metrics and highlights from the earnings report.
Key Financial Metrics
- Total Revenue: $699 million
- Growth: 2% reported growth compared to $684 million in Q3 2024.
-
Organic Growth: 1%, reflecting slight improvements despite tough market conditions.
-
Earnings Per Share (EPS):
- GAAP EPS: $0.40
- Decrease: 48% from $0.77 in Q3 2024.
-
Adjusted EPS from Continuing Operations: $1.18
- Decrease: 7.8% from $1.28 in Q3 2024.
-
Operating Income (GAAP from Continuing Operations): $82 million
- Decrease: 16.3% from $98 million in Q3 2024.
- Operating Profit Margin (GAAP): 11.7%
-
Decrease: from 14.3% in Q3 2024.
-
Adjusted Operating Income: $182 million
- Decrease: 5.7% from $193 million in Q3 2024.
- Adjusted Operating Profit Margin: 26.1%
- Decrease: from 28.3% in Q3 2024.
Segment Performance
- Life Sciences:
- Revenue: $343 million
- Growth: 1% from $339 million in Q3 2024; organic revenue was flat.
- Adjusted Operating Income: $101 million
- Decrease: 9.1% from $111 million in Q3 2024.
-
Adjusted Operating Profit Margin: 29.5%
- Decrease: from 32.6% in Q3 2024.
-
Diagnostics:
- Revenue: $356 million
- Growth: 3% from $345 million in Q3 2024; organic growth was 2%.
- Adjusted Operating Income: $89 million
- Decrease: 6% from $94 million in Q3 2024.
- Adjusted Operating Profit Margin: 25.1%
- Decrease: from 27.2% in Q3 2024.
Share Repurchase Authorization
- Revvity’s Board of Directors has authorized a new $1 billion share repurchase program, replacing the previous program that was announced in October 2024.
Full-Year 2025 Guidance
- Revenue Guidance: Revised to $2.83-$2.88 billion.
- Organic Growth Guidance: Reaffirmed at 2% to 4%.
- Adjusted EPS Guidance: Raised to a range of $4.90 to $5.00.
Additional Notes
- Revvity’s executives expressed confidence in the company’s performance and outlook moving forward, with expectations for continued growth and success into 2026.
Conclusion
Revvity, Inc.’s Q3 2025 results show a mixed performance across key financial metrics. While revenue growth is slightly positive, both GAAP and adjusted EPS, along with profit margins, saw reductions compared to the previous year’s quarter. The company’s new share repurchase program is a strategic move to potentially enhance shareholder value moving forward.
For detailed information and live Q&A, Revvity will host a webcast discussing these earnings at 8:00 a.m. Eastern Time on October 27, 2025.
Important Metrics Summary
| Metric | Q3 2025 | Q3 2024 | % Change |
|---|---|---|---|
| Revenue | $699 million | $684 million | 2% reported growth |
| GAAP EPS | $0.40 | $0.77 | -48% decrease |
| Adjusted EPS | $1.18 | $1.28 | -7.8% decrease |
| GAAP Operating Income | $82 million | $98 million | -16.3% decrease |
| Adjusted Operating Income | $182 million | $193 million | -5.7% decrease |
| Operating Profit Margin | 11.7% | 14.3% | -1.6 pp |
| Adjusted Operating Profit Margin | 26.1% | 28.3% | -2.2 pp |
| Life Sciences Revenue | $343 million | $339 million | 1% growth |
| Diagnostics Revenue | $356 million | $345 million | 3% growth |
### CONDENSED CONSOLIDATED INCOME STATEMENTS
(In thousands, except per share data)
| September 28, 2025 | September 29, 2024 | September 28, 2025 | September 29, 2024 | |
|---|---|---|---|---|
| Revenue | $698,949 | $684,049 | $2,083,995 | $2,025,654 |
| Cost of revenue | $324,345 | $299,233 | $941,289 | $900,285 |
| Selling, general and administrative expenses | $241,911 | $237,521 | $740,156 | $749,742 |
| Research and development expenses | $50,797 | $49,144 | $157,664 | $147,636 |
| Operating income from continuing operations | $81,896 | $98,151 | $244,886 | $227,991 |
| Interest income | -$6,925 | -$22,764 | -$25,351 | -$63,362 |
| Interest expense | $22,771 | $24,383 | $68,672 | $73,497 |
| Change in fair value of investments | $4,602 | -$7,004 | $3,484 | -$13,975 |
| Other expense, net | $5,763 | $3,179 | $21,364 | $10,263 |
| Income from continuing operations, before income taxes | $55,685 | $100,357 | $176,717 | $221,568 |
| Provision for income taxes | $8,464 | $6,971 | $32,605 | $26,880 |
| Income from continuing operations | $47,221 | $93,386 | $144,112 | $194,688 |
| (Loss) income from discontinued operations | -$569 | $981 | -$1,275 | -$18,948 |
| Net income | $46,652 | $94,367 | $142,837 | $175,740 |
| Diluted earnings per share: Income from continuing operations | $0.41 | $0.76 | $1.22 | $1.58 |
| (Loss) income from discontinued operations | -$0.01 | $0.01 | -$0.01 | -$0.15 |
| Net income | $0.40 | $0.77 | $1.21 | $1.42 |
| Weighted average diluted shares of common stock outstanding | 115,463 | 123,026 | 117,735 | 123,336 |
### CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
| September 28, 2025 | December 29, 2024 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $931,386 | $1,163,396 |
| Accounts receivable, net | $680,259 | $632,400 |
| Inventories, net | $379,917 | $367,587 |
| Other current assets | $152,226 | $186,225 |
| Total current assets | $2,143,788 | $2,349,608 |
| Property, plant and equipment, net | $497,088 | $482,217 |
| Operating lease right-of-use assets, net | $171,078 | $167,716 |
| Intangible assets, net | $2,425,926 | $2,640,921 |
| Goodwill | $6,600,631 | $6,463,619 |
| Other assets, net | $300,441 | $288,397 |
| Total assets | $12,138,952 | $12,392,478 |
| Current liabilities: | ||
| Current portion of long-term debt | $583,844 | $242 |
| Accounts payable | $175,800 | $167,463 |
| Accrued expenses and other current liabilities | $463,099 | $485,395 |
| Total current liabilities | $1,222,743 | $653,100 |
| Long-term debt | $2,630,693 | $3,150,476 |
| Long-term liabilities | $755,155 | $770,523 |
| Operating lease liabilities | $154,465 | $151,505 |
| Total liabilities | $4,763,056 | $4,725,604 |
| Total stockholders’ equity | $7,375,896 | $7,666,874 |
| Total liabilities and stockholders’ equity | $12,138,952 | $12,392,478 |
